Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction

Telehealth platforms are prescribing GLP-1 drugs off-label for substance use disorder, according to STAT News, moving ahead of any FDA approval for that indication. The report, published October 22, describes a pattern in which telehealth services promote the medications to patients seeking help with addiction, despite the absence of regulatory clearance for this use.

STAT News reports that experts are concerned about the fragmentation of care that results when prescribing happens through telehealth channels rather than through coordinated addiction treatment. Patients receiving GLP-1 prescriptions this way may not be connected to the broader clinical support, monitoring, or follow-up that addiction treatment typically involves. The report notes this separation raises the possibility that patients are exposed to risks that remain unknown, since the drugs have not been studied or approved for substance use disorder specifically.

The piece situates this development within a wider trend of telehealth platforms extending prescribing practices beyond approved indications, aided by the speed and reach of remote, technology-driven care models. STAT News frames the central tension as one between patient access and demand on one side, and the absence of regulatory and clinical infrastructure to support that access safely on the other.

The report does not specify which companies or platforms are involved, nor does it quantify how many patients have received such prescriptions.